| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 39, 773-781, Copyright © 1993 by American Association for Clinical Chemistry
SM Marcovina, JJ Albers, LO Henderson and WH Hannon
Department of Medicine, University of Washington, Seattle 98103.
In the third phase of the International Federation of Clinical Chemistry (IFCC) study for the standardization of apolipoprotein (apo) measurements, the preparation SP1-01, selected as the candidate international reference material for apo A-I, was investigated for its ability to transfer an accuracy-based value to the immunoassay calibrators and to produce comparability of the values for patients' samples. An apo A-I value of 1.50 g/L (SD 0.08 g/L) was assigned to SP1- 01 by a highly standardized RIA calibrated with purified apo A-I for which the mass value had been determined by amino acid analysis. According to a common detailed protocol, the participants transferred the mass value from SP1-01 to the calibrator of each method. To confirm that uniformity of calibration ensures comparability of the values over a wide range of apo A-I values, each laboratory analyzed 50 fresh- frozen samples from individual donors, using an approach similar to that adopted by the Cholesterol Reference Laboratory Network. The consensus mean value for each sample was in excellent agreement with the value assigned by the Northwest Lipid Research Laboratories, with the average absolute bias between assigned and consensus value being 0.01 g/L. The among-laboratory CV on each of the 50 samples ranged from 2.1% to 5.6% (mean 3.6%), demonstrating that comparable apo A-I results can be obtained by a variety of immunochemical methods through the use of certified reference material. Based on the results obtained in these studies, SP1-01 has been approved as Apolipoprotein A-I International Reference Material by the World Health Organization.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  A. M. Baca and G. R. Warnick Estimation of LDL-Associated Apolipoprotein B from Measurements of Triglycerides and Total Apolipoprotein B Clin. Chem., May 1, 2008; 54(5): 907 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Crawford, A. S. Nord, M. D. Badzioch, J. Ranchalis, L. A. McKinstry, M. Ahearn, C. Bertucci, C. Shephard, M. Wong, M. J. Rieder, et al. A common VLDLR polymorphism interacts with APOE genotype in the prediction of carotid artery disease risk J. Lipid Res., March 1, 2008; 49(3): 588 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. van der Steeg, S. M. Boekholdt, E. A. Stein, K. El-Harchaoui, E. S.G. Stroes, M. S. Sandhu, N. J. Wareham, J. W. Jukema, R. Luben, A. H. Zwinderman, et al. Role of the Apolipoprotein B-Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case-Control Analysis in EPIC-Norfolk Ann Intern Med, May 1, 2007; 146(9): 640 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Saczynski, L. White, R. L. Peila, B. L. Rodriguez, and L. J. Launer The Relation between Apolipoprotein A-I and Dementia: The Honolulu-Asia Aging Study Am. J. Epidemiol., May 1, 2007; 165(9): 985 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.C. Chan and G.F. Watts Apolipoproteins as markers and managers of coronary risk QJM, May 1, 2006; 99(5): 277 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Meisinger, H. Loewel, W. Mraz, and W. Koenig Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study Eur. Heart J., February 1, 2005; 26(3): 271 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Rifai, G. R. Cooper, W. V. Brown, W. Friedewald, R. J. Havel, G. L. Myers, and G. R. Warnick Clinical Chemistry Journal Has Contributed to Progress in Lipid and Lipoprotein Testing for Fifty Years Clin. Chem., October 1, 2004; 50(10): 1861 - 1870. [Full Text] [PDF]
|
|
|
|
|
|
M. Averina, O. Nilssen, T. Brenn, J. Brox, V. L. Arkhipovsky, and A. G. Kalinin Factors behind the Increase in Cardiovascular Mortality in Russia: Apolipoprotein AI and B Distribution in the Arkhangelsk Study 2000 Clin. Chem., February 1, 2004; 50(2): 346 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Jarvik, T. S. Hatsukami, C. Carlson, R. J. Richter, R. Jampsa, V. H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G. D. Schellenberg, et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Luc, J.-M. Bard, J. Ferrieres, A. Evans, P. Amouyel, D. Arveiler, J.-C. Fruchart, P. Ducimetiere, and on behalf of the PRIME Study Group Value of HDL Cholesterol, Apolipoprotein A-I, Lipoprotein A-I, and Lipoprotein A-I/A-II in Prediction of Coronary Heart Disease: The PRIME Study Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Levinson High Density- and Beta-Lipoprotein Screening for Risk of Coronary Artery Disease in the Context of New Findings on Reverse Cholesterol Transport Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 123 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E Roeters van Lennep, H.T. Westerveld, D.W. Erkelens, and E. E van der Wall Risk factors for coronary heart disease: implications of gender Cardiovasc Res, February 15, 2002; 53(3): 538 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sakai, V. S. Kamanna, and M. L. Kashyap Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1783 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Marcovina, J. J. Albers, A. M. Scanu, H. Kennedy, F. Giaculli, K. Berg, R. Couderc, F. Dati, N. Rifai, I. Sakurabayashi, et al. Use of a Reference Material Proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to Evaluate Analytical Methods for the Determination of Plasma Lipoprotein(a) Clin. Chem., December 1, 2000; 46(12): 1956 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Jarvik, L. S. Rozek, V. H. Brophy, T. S. Hatsukami, R. J. Richter, G. D. Schellenberg, and C. E. Furlong Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2441 - 2447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Emanuele, N. Azad, C. Abraira, W. Henderson, J. Colwell, S. Levin, F. Nuttall, J. Comstock, C. Sawin, C. Silbert, et al. Effect of Intensive Glycemic Control on Fibrinogen, Lipids, and Lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus Arch Intern Med, December 1, 1998; 158(22): 2485 - 2490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials Clin. Chem., August 1, 1998; 44(8): 1641 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Espeland, S. M. Marcovina, V. Miller, P. D. Wood, C. Wasilauskas, R. Sherwin, H. Schrott, and T. L. Bush Effect of Postmenopausal Hormone Therapy on Lipoprotein(a) Concentration Circulation, March 17, 1998; 97(10): 979 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schrott, A. G. Fereshetian, R. H. Knopp, H. Bays, P. H. Jones, T. W. Littlejohn, R. McLain, and D. M. Black A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(2): 119 - 123. [Abstract] [PDF]
|
|
|
|
|
|
M. S. Graziani, L. Zanolla, G. Righetti, C. Marchetti, P. Mocarelli, and S. M. Marcovina Plasma apolipoproteins A-I and B in survivors of myocardial infarction and in a control group Clin. Chem., January 1, 1998; 44(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. McNamara, E. T. Leary, F. Ceriotti, C. M. Boersma-Cobbaert, T. G. Cole, D. J. Hassemer, M. Nakamura, C. J. Packard, D. W. Seccombe, M. M. Kimberly, et al. Point Status of lipid and lipoprotein standardization Clin. Chem., August 1, 1997; 43(8): 1306 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Sniderman Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making Clin. Chem., August 1, 1997; 43(8): 1310 - 1314. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. K. Parsons, S. X. Skapek, E. J. Neufeld, C. Kuhlman, M. L. Young, M. Donnelly, J. D. Brunzell, J. D. Otvos, S. E. Sallan, and N. Rifai Asparaginase-Associated Lipid Abnormalities in Children With Acute Lymphoblastic Leukemia Blood, March 15, 1997; 89(6): 1886 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Y. Craig, S. E. Poulin, G. E. Palomaki, L. M. Neveux, R. F. Ritchie, and T. B. Ledue Oxidation-Related Analytes and Lipid and Lipoprotein Concentrations in Healthy Subjects Arterioscler. Thromb. Vasc. Biol., June 1, 1995; 15(6): 733 - 739. [Abstract] [Full Text]
|
|
|
|
|
|
J. W. Nawrocki, S. R. Weiss, M. H. Davidson, D. L. Sprecher, S. L. Schwartz, P.-J. Lupien, P. H. Jones, H. E. Haber, and D. M. Black Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor Arterioscler. Thromb. Vasc. Biol., May 1, 1995; 15(5): 678 - 682. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
